Understand the source comparison
GHRP-6 Acetate Before and After: Comparison Table
The table below compares GHRP-6 acetate to other commonly researched growth hormone secretagogues based on mechanism, typical dosing, timeline to observable changes, and primary research applications. | Peptide | Mechanism of Action | Typical Research Dose | T
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The table below compares GHRP-6 acetate to other commonly researched growth hormone secretagogues based on mechanism, typical dosing, timeline to observable changes, and primary research applications.
- | Peptide | Mechanism of Action | Typical Research Dose | Timeline to IGF-1 Elevation | Timeline to Body Composition Changes | Primary Appetite Effect | Professional Assessment ||—|—|—|—|—|—|| GHRP-6 Acetate | GHS-R1a agonist (ghrelin mimetic); stimulates endogenous GH pulse | 100–300 mcg 2–3×/day subcutaneous | 10–14 days | 8–12 weeks | Strong appetite stimulation 30–60 min post-injection | Best for research focused on recovery, lean mass accrual, and anabolic signaling; appetite effect complicates fat loss protocols unless meal timing is tightly controlled || GHRP-2 | GHS-R1a agonist; similar to GHRP-6 but reduced ghrelin activity | 100–300 mcg 2–3×/day subcutaneous | 10–14 days | 8–12 weeks | Mild appetite stimulation | Preferred alternative to GHRP-6 when appetite stimulation is undesirable; nearly identical GH response with less pronounced hunger signaling || Ipamorelin | Selective GHS-R agonist; minimal ghrelin cross-reactivity | 200–300 mcg 2–3×/day subcutaneous | 12–18 days | 1